Isomorphic Labs, an Alphabet subsidiary specializing in AI-driven drug discovery, announced a major milestone in pharmaceutical history on July 7, 2025. As reported by leading industry publications, including STAT+ and Yahoo Finance, the company has received approval to begin the first human clinical trials for two oncology drugs whose molecules were entirely designed using artificial intelligence. This moment is a turning point for the entire industry, as it marks the transition from theoretical AI successes in protein modeling and molecule discovery to their real-world practical application in medicine. The drugs entering the clinical trial phase are intended for chemotherapy and target specific proteins that play a key role in the growth of cancer tumors. The entire creation process, from identifying the target to designing the molecular structure capable of effectively binding to it, was carried out using Google DeepMinds AlphaFold 3 platform, on which Isomorphic Labs technology is based. The use of AI has dramatically reduced the time required for the preclinical development phase, which traditionally takes many years. Isomorphic Labs managed to complete this stage in a record short time, which could potentially make the process of bringing new drugs to market significantly cheaper and faster in the futuro. Although the success of the clinical trials is not guaranteed, the very fact that they have begun is a powerful confirmation that the AI-approach to drug discovery works. This ushers in a new era in medicine, where artificial intelligence becomes a key partner for scientists in the fight against the most complex diseases.
Isomorphic Labs Begins First Clinical Trials of AI-Designed Drugs
